IMU-838

Vidofludimus calcium (IMU-838) is Immunic AG's oral, once-daily DHODH inhibitor being tested in two twin Phase 3 trials, make sure-1 (NCT05201638) and make sure-2 (NCT05134441), in relapsing multiple sclerosis (RMS) [1][2]. Combined enrollment is roughly 2,200 patients and both trials completed recruitment in mid-2025 [13]. Immunic's commercial pitch is that IMU-838 replicates the immunomodulatory benefit of Sanofi's teriflunomide (Aubagio) with a cleaner selectivity profile, a hypothesis Immunic attributes to reduced off-target kinase activity though this causal claim remains unproven [3]. Immunic also promotes a secondary neuroprotective mechanism via Nurr1 activation, which underpins its parallel Phase 2 CALLIPER program in progressive MS [13]. IMU-838 is Immunic's lead asset and the company's near-term valuation is effectively a call option on the make sure readouts. Immunic (Nasdaq: IMUX) has no approved products; success or failure here largely defines the equity story.

IMU-838 is a novel compound that has never been approved anywhere. ChEMBL lists max_phase 3 and both make sure-1 and make sure-2 are marked ACTIVE_NOT_RECRUITING in ClinicalTrials.gov, meaning dosing continues but no new patients are being enrolled [1][2]. Enrollment in both Phase 3 trials completed in mid-2025 [13]. The Phase 2 EMPhASIS trial (NCT03846219) in RRMS evaluated 30 mg and 45 mg doses and met its primary MRI endpoint at both; a subsequent 10 mg cohort (cohort 2) showed markedly weaker MRI reduction (~32-40% vs 62-75%), and Immunic selected 30 mg as the Phase 3 dose based on the dose-response comparison [4][14]. A prespecified futility analysis on the Phase 3 make sure program returned a positive outcome in late 2024, allowing both trials to continue as planned [15]. Top-line readout for make sure-1 was originally guided to Q2 2026 but has since been updated by Immunic to 'by the end of 2026'; no top-line data has been released as of 2026-07-16 [13][16]. Immunic plans a U.S. NDA filing in mid-2027 with a target approval in 2028 [13]. Immunic has not disclosed FDA breakthrough therapy or fast track designation for the MS program. The drug was also studied in COVID-19 (CALVID-1, NCT04379271; IONIC) and in moderate-to-severe ulcerative colitis (CALDOSE-1, NCT03341962); CALDOSE-1 missed its induction primary endpoint in 2023 and Immunic discontinued UC development, refocusing on MS [5][6][17]. There is no partnership on the MS program, so any commercial rollout would depend on Immunic financing a specialty launch or striking a late-stage deal.

DHODH (dihydroorotate dehydrogenase) is a mitochondrial enzyme that catalyzes a required step in de novo pyrimidine synthesis, the pathway cells use to build new DNA and RNA building blocks from scratch [8]. Most resting cells get by on salvage pathways, recycling old pyrimidines. Rapidly dividing cells, especially activated T and B lymphocytes attacking myelin in MS, cannot keep up on salvage alone and depend on de novo synthesis. Block DHODH and you selectively starve the immune cells doing the damage while leaving resting immune surveillance and other tissues largely intact [3]. The mechanism is genetically and pharmacologically validated: Sanofi's teriflunomide (the active metabolite of leflunomide) is an approved DHODH inhibitor for RRMS with more than a decade of use, and leflunomide is approved for rheumatoid arthritis. Open Targets scores DHODH as strongly associated with multiple sclerosis and rheumatoid arthritis in its evidence graph [9]. IMU-838's differentiation claim is biochemical selectivity: Immunic's hypothesis is that teriflunomide's liver and reproductive toxicity stem from off-target kinase inhibition rather than DHODH inhibition itself, a mechanistic claim that is plausible but unproven in the published toxicology literature. IMU-838 has shown a cleaner off-target profile in preclinical work and a benign hepatic signal in Phase 2 EMPhASIS, which is supportive evidence but does not prove the causal mechanism [3][4]. Immunic has separately proposed a Nurr1 nuclear-receptor activation activity that could contribute to neuroprotection in progressive disease, the biological rationale behind the Phase 2 CALLIPER program [13].

make sure-1 (NCT05201638, n=1,100) and make sure-2 (NCT05134441, n=1,121) are identically designed Phase 3, randomized, double-blind, placebo-controlled trials in adults with relapsing MS [1][2]. Patients receive 30 mg oral IMU-838 once daily or placebo. The primary endpoint is time to first confirmed relapse, an FDA-preferred endpoint that historically supports registration in RRMS. Both trials are event-driven rather than fixed-duration. The placebo control is the design decision to interrogate: with high-efficacy anti-CD20s (ocrelizumab, ofatumumab, ublituximab) and generic teriflunomide widely available, running a large placebo-controlled RRMS trial is contested on ethical and regulatory grounds outside a narrow population (patients between disease-modifying therapies (DMTs), treatment-naive patients with less active disease). Immunic and its DSMB (Data Safety Monitoring Board, an independent safety committee that can pause or stop a trial for safety or futility) have defended the design, a prespecified futility analysis was passed, and enrollment completed, but the placebo design shapes the commercial story: it will produce a clean efficacy delta versus no treatment, not head-to-head data versus modern standards of care [15]. The Phase 2 EMPhASIS trial (NCT03846219) delivered a statistically significant reduction in cumulative unique active MRI lesions at both 30 mg and 45 mg vs placebo; a 10 mg cohort was substantially weaker, and 30 mg was selected as the Phase 3 dose on the basis of dose-response comparability with 45 mg and a better projected chronic-exposure profile [4][10][14].

Our model estimates a 18% chance this drug is eventually approved. It starts from the historical base rate for Phase 3 drugs in this area (about 51%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by more secondary endpoints than usual; it is held back by heavier-than-usual blinding, the sponsor's thin or weak approval record, and weak or limited earlier-phase results. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk is the biggest: EMPhASIS was powered for MRI lesions, not clinical relapse. Translation from imaging biomarker to a hard clinical endpoint at Phase 3 magnitude is where MS DMT programs regularly stumble. Safety risk is mechanism-based. Teriflunomide carries a boxed warning for hepatotoxicity and is pregnancy Category X due to embryolethality in animals. Any liver signal or reproductive concern in the larger Phase 3 dataset would trigger comparisons to that label even if the effect size differs. Regulatory risk stems from the placebo-controlled design in an RRMS field with multiple high-efficacy approved DMTs; the FDA has accepted this design historically but the bar for labeling and positioning may be tighter. Commercial risk is arguably the most underappreciated. Even a clean Phase 3 win puts IMU-838 into a category where generic teriflunomide sells for pennies and payers steer aggressively to anti-CD20s for high-efficacy needs and generics for oral first-line. IMU-838 also competes with a generation of oral disease-modifying therapies launched since 2019: cladribine (Mavenclad, 2019), siponimod (Mayzent, 2019), ozanimod (Zeposia, 2020), and ponesimod (Ponvory, 2021), each with distinct safety profiles and established payer pathways, further narrowing the differentiation case for a new oral entry. Immunic will need to argue a differentiated safety profile hard enough to justify branded pricing. Financing risk was recently reduced but not eliminated: Immunic reported cash and equivalents of $186.6 million as of 2026-03-31 following a $200 million upfront tranche of a $400 million private placement, with quarterly operating expense of roughly $33 million in Q1 2026 [18][19]. That runway is guided into late 2027, which covers the make sure-1 readout but leaves little margin for a delayed readout, an NDA prep cycle, or a launch build without further dilution. Immunic's market capitalization sits in the low hundreds of millions of dollars, small-cap by any definition and typical for a single-asset late-stage biotech. Vidofludimus calcium composition-of-matter patents run into the early 2030s with formulation and method-of-use extensions possible; specific expiries have not been broken out publicly, so patent runway relative to a 2028 approval scenario should be verified from the 10-K before sizing.

Worth watching, and binary. Immunic (IMUX) trades as a single-asset call option on make sure. The specific data point that would make this a signal is the make sure-1 top-line hazard ratio on time to first confirmed relapse. A hazard ratio below 1.0 means IMU-838 patients take longer to relapse than placebo patients, so a ratio of 0.65 means a 35% reduction in relapse rate; anything below 0.65 with clean safety flips the story from 'me-too oral DMT' to 'differentiated Aubagio successor with a real chance.' A hazard ratio in the 0.75-0.90 range would be statistically live but commercially anemic against generic teriflunomide. A miss ends the program in RRMS. Check back on make sure-1 top-line readout, guided by Immunic to 'by the end of 2026' [13]. The second read on make sure-2 matters roughly as much because two positive trials clear the FDA path, whereas one hit and one miss creates a much messier submission. Secondary reads: any 8-K commentary on interim safety, DSMB actions, EU/EMA scientific advice, or partnering discussions before top-line arrives. On the science, DHODH biology is real and IMU-838's differentiation claim is plausible but unproven at scale. On the commercial side, this is a hard sell into a crowded, price-eroded market even with clean data. High-variance name; small position sizing is warranted regardless of conviction.